SCHEMBL1975010

SCHEMBL1975010

Cc1nc(NC(=O)c2ccc3[nH]c(Nc4c(Cl)cccc4Cl)nc3c2)cc2c1CCCC2

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.43
RAB9A P51151 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPK1 P28482 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
PTGES O14684 6/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HTT P42858 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LCK P06239 4/20 0.38
IRAK4 Q9NWZ3 2/20 0.38
MCL1 Q07820 1/20 0.38
HPGD P15428 1/20 0.38
HDAC11 Q96DB2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16352181 0.85 PTGES (0.45) PTGES
SCHEMBL13392916 0.85 SORT1 (0.45) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL16352180 0.82 HDAC6 (0.45) NPC1RAB9ANPSR1SMN1; SMN2KDM4E
SCHEMBL13393101 0.82 NPC1 (0.47) NPC1RAB9ANPSR1SMN1; SMN2KDM4E
SCHEMBL16364109 0.82 LCK (0.52) NPC1RAB9ANPSR1SMN1; SMN2KDM4E
SCHEMBL1974207 0.81 NPC1 (0.54) NPC1RAB9ANPSR1SMN1; SMN2KDM4E
SCHEMBL1970688 0.81 LCK (0.45) NPC1RAB9ASMN1; SMN2PTGESKMT2A
SCHEMBL1973509 0.80 MAPT (0.55) NPC1RAB9ANPSR1SMN1; SMN2PTGES
SCHEMBL1973147 0.80 IRAK4 (0.58) NPC1RAB9ANPSR1SMN1; SMN2KDM4E
SCHEMBL13393449 0.80 MAPT (0.50) NPC1RAB9ASMN1; SMN2PTGESKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334652-A1 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS Boehringer Ingelheim International GmbH (DE) 2011-06-22 EP claimed
US-8916599-B2 1H-benz imidazole-5-carboxamides as anti-inflammatory agents OREXO AB (SE) 2014-12-23 US disclosed
US-8916599-B2 1H-benz imidazole-5-carboxamides as anti-inflammatory agents OREXO AB (SE) 2014-12-23 US disclosed
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents MAPRE2, MAPRE1, H1-4 NPC1 4650/4885RAB9A 867/4885NPSR1 2508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.